Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors

Brett H Herzog,Saiama N Waqar,Siddhartha Devarakonda,Jeffrey P Ward,Feng Gao,Ramaswamy Govindan,Daniel Morgensztern

Lung Cancer（2022）

引用 3|浏览6

暂无评分

摘要

•The options for patients with previously treated NSCLC are limited.•Immune checkpoint inhibitors and anti-VEGF drugs are synergistic.•The combination of ramucirumab with atezolizumab was well tolerated.•Despite the low response rate, the overall survival was promising.

查看译文

关键词

NSCLC,VEGF inhibition,Immune checkpoint inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要